Skip to main content

ficlatuzumab

·Code: AV-299

ficlatuzumab: 2 clinical trials tracked.

ficlatuzumab evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about ficlatuzumab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trial Registry Records (2)

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

NCT06064877Registry updated 2026-04-09·Phase 3·AVEO
Recruiting

Primary endpoint: To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

InterventionalRandomizedquadruple410 targetStarted 2024-01Completion 2027-1150 sites · Australia, Belgium, Bulgaria, Canada…AVEO Pharmaceuticals, Inc.

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

NCT03013998Registry updated 2026-09-03·Phase 2/Phase 3
Recruiting

Primary endpoint: BAML-16-001-M1: Proportion of patients for whom molecular, immunophenotypic, and/or biochemical studies are completed in < 7 calendar days for assignment of treatment

Interventionalopen3,000 targetStarted 2016-11Completion 2032-1231 sites · United StatesBeat AML, LLC